Cerivastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C26H34FNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AM91H2KS67, chemically known as 6-heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (s-(r*,s*-(e)))- but generally known as cerivastatin, which bears US NIH Compound Identifier 446156. European Medicines Agency schedules Cerivastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07440MIG. The term CERIVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). World Health Organization schedules cerivastatin in its Anatomical Therapeutic Chemical (ATC) Classification. CERIVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule cerivastatin under HS 29333999 and SITC 51574. As of Q4 2014, CERIVASTATIN remains the US FDA Preferred Term for this commodity. Cerivastatin bears US NLM identifiers UMLS ID C0528023 and NCI Concept Code C65308. SMILES: Fc1ccc(c2c(c(nc(c2/C=C/C(O)CC(O)CC(=O)O)C(C)C)C(C)C)COC)cc1.